Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innocrin Pharmaceuticals has started a new Phase II trial of once-daily oral VT-464 in patients with castration-resistant prostate cancer (CRPC) progressing on enzalutamide or abiraterone.
Subscribe to our email newsletter
VT-464 is an oral medication given without prednisone that may represent an improved therapy for men with CRPC and it works by selectively inhibiting CYP17 lyase, a target of abiraterone, and blocks the AR, similar to enzalutamide
The company develops small-molecule CYP17 lyase-selective inhibitors to treat hormonally-dependent breast and prostate cancers resistant to standard hormonal therapy.
Innocrin CEO William Moore said: "This study will help inform why 30 to 40% of men with CRPC do not initially respond to the currently approved drugs, why other men become resistant to them, and which patients will most likely benefit from VT-464.
"The study will also inform whether the tumors of these patients express reported biomarkers of resistance to abiraterone and enzalutamide, including androgen receptor (AR) mutations and splice variants such as AR-v7, or the glucocorticoid receptor, and whether or not, similar to preclinical models, they will respond to VT-464."
The Phase II trial is led by Memorial Sloan Kettering chief of Genitourinary Oncology Service Howard Scher, who is the recipient of a prestigious $1m Challenge Award from the Prostate Cancer Foundation (PCF).